Red cell transfusion in acute myeloid leukaemia (REAL)

Not Applicable

Completed

• Conditions: Specialty: Cancer, Primary sub-specialty: Haematological Oncology; Cancer; UKCRC code/ Disease: Cancer/ Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissu; Acute Myeloid Leukaemia

• Registration Number: ISRCTN96390716
• Lead Sponsor: HS Blood and Transplant

Brief Summary

2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35199504/ (added 05/05/2022)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-01-23
• Study Completion: 2019-11-01
• Last Update Posted: 5 September 2022

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 43

Inclusion Criteria

1. Adults aged 18 years and over
2. Diagnosis of de novo acute myeloid leukaemia (AML) or relapsed AML
3. Undergoing treatment with intensive chemotherapy with an expectation of receiving a minimum of 2 cycles (excluding stem cell transplant)

Exclusion Criteria

1. Patients for whom the attending haematologist feels allocation to either a restrictive or liberal policy of red cell transfusion is not justified (e.g. clinically significant cardiovascular disease)
2. Acute promyelocytic leukaemia (APML)
3. Patients who have been diagnosed with myelodysplasia prior to diagnosis of AML.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<br> 1. Percentage of pre-transfusion haemoglobin concentrations being within target range of the assigned red cell transfusion strategy is measured using patient notes at pre every red cell transfusion<br> 2. Achievement of at least a 15g/L difference between the mean pre-transfusion haemoglobins in the 2 randomisation groups is measured patient notes at pre every red cell transfusion<br>